21 results on '"Lacasce, A. S."'
Search Results
2. Dana-Farber Cancer Institute/Mass General Brigham Fellowship Response to the COVID-19 Pandemic
3. Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.
4. CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).
5. Response-Adapted Therapy in Aggressive Lymphoma: Not Yet Ready for Clinical Care
6. Self-stated and actual practice patterns of general medical oncologists (MO) regarding the use of predictive biomarkers to guide treatment for patients (pts) with chronic lymphocytic leukemia (CLL).
7. Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma
8. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation
9. US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816
10. Brentuximab vedotin plus AVD for non-bulky limited stage Hodgkin lymphoma: A phase II trial.
11. Targeting Epstein-Barr Virus–Associated Lymphomas
12. Targeting Epstein-Barr Virus–Associated Lymphomas
13. Helicobacter pylori–Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma
14. Cardiac Presentation of Anaplastic Large-Cell Lymphoma
15. Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy
16. Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909
17. Reply to J. Mehta
18. Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning
19. Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network
20. A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies
21. Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.